Cargando…

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients

Enfortumab vedotin (EV), an antibody–drug conjugate directed against Nectin-4, significantly prolonged survival compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vulsteke, Christof, De Cocker, Laurens, Gómez de Liaño, Alfonso, Montesdeoca, Cristina, De Meulenaere, Astrid, Croes, Lieselot, Delombaerde, Danielle, Szabados, Bernadett, Powles, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057070/ https://www.ncbi.nlm.nih.gov/pubmed/36986475 http://dx.doi.org/10.3390/ph16030375

Ejemplares similares

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
por: Jain, Rohit K, et al.
Publicado: (2020)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
por: Enescu, Christina D., et al.
Publicado: (2022)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
por: Mimura, Yuji, et al.
Publicado: (2022)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report
por: Delombaerde, Danielle, et al.
Publicado: (2022)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
por: Isoda, Bunpei, et al.
Publicado: (2023)

Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report
por: Atemnkeng, Francis, et al.
Publicado: (2023)

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
por: Miyake, Makito, et al.
Publicado: (2023)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
por: Jindal, Tanya, et al.
Publicado: (2023)

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
por: Collette, Kaylyn R., et al.
Publicado: (2022)

Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 
por: Clennon, Anna, et al.
Publicado: (2023)

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
por: Zschäbitz, Stefanie, et al.
Publicado: (2023)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
por: Homma, Takamasa, et al.
Publicado: (2023)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
por: Klümper, Niklas, et al.
Publicado: (2023)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
por: Francis, Andrea, et al.
Publicado: (2020)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
por: Thibodeau, Alexa, et al.
Publicado: (2021)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021)

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
por: Delombaerde, Danielle, et al.
Publicado: (2023)

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature
por: Vlachou, Evangelia, et al.
Publicado: (2023)

Enfortumab Vedotin-induced Hyperglycemia and Ileal Conduit Reconstruction-induced Metabolic Acidosis
por: Sato, Takaaki, et al.
Publicado: (2023)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction
por: Bansal, Aditi, et al.
Publicado: (2022)

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
por: Sarfaty, Michal, et al.
Publicado: (2021)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
por: Shahin, Ahmad, et al.
Publicado: (2022)

Temporary Tumor Shrinkage Following Enfortumab Vedotin Therapy for Metastatic Urothelial Carcinoma After Radical Cystectomy With Neoadjuvant Chemotherapy: A Case Report
por: Namiki, Sanae, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7dp86ogkae65bdu6f6534i324r